Patents by Inventor Maj HEDTJÄRN

Maj HEDTJÄRN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treatment Using Antisense Oligomers and Conjugates Targeting PCSK9
    Publication number: 20180312847
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 1, 2018
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie Wickstrom LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • ANTISENSE OLIGOMERS AND CONJUGATES TARGETING PCSK9
    Publication number: 20180216116
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: December 8, 2017
    Publication date: August 2, 2018
    Inventors: Nanna Albaek, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Oligonucleotide conjugates
    Patent number: 9879265
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 30, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20170191064
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 6, 2017
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • OLIGONUCLEOTIDE CONJUGATES
    Publication number: 20160138025
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: June 27, 2014
    Publication date: May 19, 2016
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • OLIGONUCLEOTIDE MODULATORS OF B-CELL CLL/LYMPHOMA 11A (BCL11A) AND USES THEREOF
    Publication number: 20160130582
    Abstract: The present invention provides, among other things, oligonucleotide modulators (e.g., inhibitors) of B cell lymphoma/leukemia 11A (BCL11A) and improved methods and composition for treating BCL11A-related diseases, disorders or conditions based on such modulators.
    Type: Application
    Filed: May 26, 2014
    Publication date: May 12, 2016
    Applicant: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Maj HEDTJÄRN, Niels Fisker NIELSEN
  • Short oligomer antagonist compounds for the modulation of target mRNA
    Patent number: 8580756
    Abstract: The invention provides LNA gapmer oligomers of between 10-20 nucleobases in length, which have a total of 1-3 phosphodiester internucleoside linkages. Such oligomers have been found to have superior bioavailability and have also been found to selectively accumulate in kidney cells.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: November 12, 2013
    Assignee: Santaris Pharma A/S
    Inventors: Jens Bo Rode Hansen, Henrik Orum, Henrik Frydenlund Hansen, Ellen Marie Straarup, Niels Fisker Nielsen, Maj Hedtjärn
  • SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HIF-1ALPHA
    Publication number: 20100249219
    Abstract: The present invention relates to oligomeric compounds (oligomers) of 12, 13 or 14 nucleotides in length, which target Hif-1alpha mRNA in a cell, leading to reduced expression of Hif-1alpha. Reduction of Hif-1alpha expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: April 2, 2010
    Publication date: September 30, 2010
    Inventors: Maj HEDTJÄRN, Jens Bo Rode Hansen